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ABSTRACT 
Human Respiratory Syncytial Virus (HRSV) is the major cause of acute respiratory 
infection in children (ARI) and it is responsible for substantial morbidity and mortality, 
especially in younger children. The present study had two main objectives. The first 
one was to determine the prevalence of HRSV and non-HRSV ARI in children under 
the age of 5 years at the Provincial General Hospital of Bukavu (PGHB). The second 
objective was to analyse factors associated with the risk of ARI to be diagnosed as 
lower respiratory tract infection (LRTI).  
A total of 146 children under 5 years visiting the PGHB for ARI between August and 
December 2016 were recruited. A clinical examination was made and a 
questionnaire was completed by the parent or the guardian after which a 
nasopharyngeal swab was performed to collect respiratory fluid. The sample was 
analysed by a multiplex reverse transcriptase polymerase chain reaction for the 
detection of 15 different viruses, among which HRSV A and B, Influenza A and B, 
human Rhinovirus (HRV) A/B/C, Parainfluenza (PIV) viruses 1, 2, 3 and 4, 
Adenovirus (ADV), Bocavirus, Coronavirus OC43 and 229E/NL63, Enterovirus and 
human Metapneumovirus.  
Of 146 samples collected, 84 (57.5%) displayed a positive result of at least one of the 
15 viruses. The overall prevalence of HRSV was 21.2%. HRSV A (30, 20.5%) was 
the virus the most detected, followed by HRV (24, 16.4%), PIV3 (20, 16.6) and ADV 
(7, 4.79%). The other viruses were detected in three or less cases. There were only 
11 (7.5%) of co-infection. In bivariate analyses, HRSV infection, malnutrition, younger 
age, rural settings, low income and mother illiteracy were associated with the risk of 
ARI to be diagnosed as LRTI. However, in multivariate analyses, only HRSV infection 
and younger age predicted LRTI. Children with HRSV infection had 6.45 times higher 
odds to exhibit LRTI when compared to children without HRSV infection. Older 
children (by one month) had 6% lower odds of LRTI than younger children (adjusted 
odds ratio = 0.94, 95% CI: 0.90 – 0.97, p-value = 0.004).  
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OPSOMMING 
Respiratoriese sinsitiale virus (RSV) is die hoofoorsaak van akute respiratoriese 
infeksie (ARI) by kinders en dit is verantwoordelik vir erge morbiditeit en mortaliteit, 
veral by jonger kinders. Die huidige studie het twee hoofdoelwitte gehad. Die eerste 
een was om die voorkoms van RSV en nie-RSV ARI in kinders onder die ouderdom 
van 5 jaar by die Provinsiale Algemene Hospitaal van Bukavu (PGHB) te bepaal. Die 
tweede doel was om faktore te analiseer wat verband hou met die risiko dat ARI 
gediagnoseer word as lae lugweginfeksie. 
'n Totaal van 146 kinders onder 5 jaar wat die PGHB vir ARI besoek het tussen 
Augustus en Desember 2016 is gewerf vir die studie. 'n Kliniese ondersoek is 
gedoen en 'n vraelys is deur die ouer of voog voltooi, waarna respiratoriese vloeistof 
met behulp van 'n nasofaringeale depper versamel is. Die monster is geanaliseer 
met behulp van 'n multiplex-omgekeerde transkriptase-polimerase kettingreaksie vir 
die opsporing van 15 verskillende virusse, waaronder RSV A en B, Influenza A en B, 
menslike Rhinovirus (HRV) A / B / C, Parainfluenza virus (PIV) 2, 3 en 4, Adenovirus 
(ADV), Bocavirus, Coronavirus OC43 en 229E / NL63, Enterovirus en menslike 
Metapneumovirus. 
Van 146 monsters wat versamel is, is minstens een van die 15 virusse bevestig in 84 
(57.5%) gevalle. Die algehele voorkoms van RSV was 21.2%. RSV A (30, 20.5%) 
was die virus wat die meeste bespeur is, gevolg deur HRV (24, 16.4%), PIV3 
(20,16.6) en ADV (7, 4.79%). Die ander virusse is slegs in drie of minder gevalle 
bevestig. Daar was slegs 11 (7.5%) ko-infeksie. In ŉ twee-veranderlike analise is 
RSV-infeksie, wanvoeding, jonger ouderdom, landelike woongebiede, lae inkomste 
en ongeletterdheid in moeders geassosieer met die risiko dat ARI gediagnoseer word 
as lae lugweginfeksie. In ŉ meer-veranderlike analise het slegs RSV-infeksie en 
jonger ouderdom lae lugweginfeksie voorspel. Kinders met RSV-infeksie het ŉ 6.45 
keer hoër kans gehad om lae lugweginfeksie te vertoon in vergelyking met kinders 
sonder RSV-infeksie. Ouer kinders (met een maand) het ŉ 6% laer kans gehad op 
lae lugweginfeksie as jonger kinders (aangepaste kansverhouding = 0.94, 95% CI: 
0.90 – 0.97, p-waarde = 0.004). 
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CHAPTER 1: INTRODUCTION 
 Rationale 1.1
Human Respiratory syncytial virus (HRSV) is a major cause of acute respiratory 
infection (ARI) in children worldwide (Kim et al., 2000; Tsolia et al., 2003; Kwofie et 
al., 2012). It is responsible for seasonal outbreaks (Madhi et al., 2006; Bloom-
Feshbach et al., 2013) and is associated with substantial morbidity and mortality 
rates, especially in people with some underlying conditions (Anderson et al., 2016). 
Every year, HRSV is a source of significant hospital admissions in young children 
with a considerable rate of mortality in high-risk groups (Szabo et al., 2013; Reeves 
et al., 2017). HH ARI has a major impact on healthcare resources and costs (Forbes 
et al., 2010; Anderson et al., 2017). Furthermore, there is growing evidence that 
HRSV ARI in childhood is linked to long-term impaired lung function that can 
manifest as recurrent wheezing or asthma (Fauroux et al., 2017). 
Various socio-demographic factors are associated with severe HRSV ARI. Children 
born before 37 weeks of gestational age tend to develop more severe HRSV ARI 
than those born at term (Shi et al., 2015) and those under 1 year experience the 
highest incidence of HRSV-associated hospitalizations (Rowlinson et al., 2013). 
Severe stunting, low birthweight, crowding, high numbers of siblings under 6 years in 
a household, lack of exclusive breast feeding and maternal smoking have been 
shown to be major factors associated with severe HRSV ARI (McNamara & Smyth, 
2002; Okiro et al., 2008; Jackson et al., 2013).  
Non-HRSV virus co-infection is common in HRSV-infected children (Yoshida et al., 
2013). The following non-HRSV viruses are known to be involved in co-infection 
during HRSV infection: Influenza virus, Human rhinovirus (HRV), Adenovirus (ADV), 
Coronavirus (CoV), Parainfluenza virus (PIV), Human metapneumovirus (HMPV), 
Human bocavirus (HBoV) and Enterovirus (EV). Non-HRSV virus co-infection may 
increase the severity of HRSV disease (Harada et al., 2013).  
Investigating the epidemiology of viral respiratory infections, understanding their 
interaction with the human body and increasing the knowledge on the disease 
progression can be a valuable tool to contain their spread. Infection prevention and 
control (IPC) measures, such as strict observance of hand washing, use of gloves 
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and gowns by caregivers, limiting visitors during HRSV season, active surveillance 
for HRSV infection and cohorting of infected patients and caregivers, are efficient in 
limiting the spread of the virus (Collins & Karron, 2013). Moreover, passive 
immunization with palivizumab (a monoclonal antibody) is used in the prevention of 
HRSV infection in children with a high risk of a severe disease.  
To date, the burden of HRSV infection in children in the Democratic Republic of 
Congo (DRC), especially in the East part of the country, has not been studied. 
Moreover IPC measures are not strictly practised and high-risk children do not 
receive palivizumab for passive immunization against the virus due to its very high 
cost. This study will bring some insight on respiratory infections in this country and 
propose some recommendations on how to improve children’s health.  
 Hypotheses:  1.2
Hypothesis 1: The prevalence of HRSV is higher in ARI in children under 5 years of 
age when compared to other respiratory viruses.  
Hypothesis 2: HRSV, as well as some socio-demographic factors and medical 
features, is associated with the risk of ARI to be diagnosed as lower respiratory tract 
infections (LRTI) in children under the age of 5 years. 
 Aim:  1.3
To investigate the epidemiological features of respiratory infections in paediatric 
patients visiting the Provincial General Hospital of Bukavu (PGHB).  
 Objectives: 1.4
Ø To collect socio-demographic information, clinical data and nasal swabs from 
children under the age of 5 years 
Ø To gather literature on HRSV infection 
Ø To determine the prevalence of HRSV ARI and non-HRSV ARI in children 
under the age of 5 years. 
Ø To identify socio-demographic and clinical characteristics associated with the 
risk of ARI to be diagnosed as LRTI in children under the age of 5 years. 
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CHAPTER 2: LITERATURE REVIEW 
In this section, the HRSV structure and replication cycle, its interaction with the host 
immunity, epidemiology, diagnosis, as well as prevention and treatment, will be 
briefly reviewed.  
 The Infectious Agent: 2.1
 The Virion: 2.1.1
HRSV belongs to the order of Mononegavirales, the family of Pneumoviridae, the 
genus of Orthopneumovirus and the species of Human orthopneumovirus (Rima et 
al., 2017). Its virion consists of a nucleocapsid surrounded by a lipid membrane 
derived from the bi-layer plasma membrane of the host (Figure 2.1). Virions 
produced in cell culture consist of spherical particles of 100–350 nm in diameter and 
long filaments that usually predominate and are 60–200 nm in diameter and up to 10 
µm in length (Jeffree et al., 2003).   
Electron tomography and calculation of subtomogram averages using Dynamo™ 
software have revealed that the HRSV nucleocapsid is helical left-handed with a 
pitch of 68 Angstrom (Bakker et al., 2013).  
 
Figure 2.1 Electron micrograph image of an HRSV virion budding from an 
infected cell (Garofalo et al., 2016). 
 The Genome 2.1.2
The HRSV genome is a non-segmented negative-sense single-stranded ribonucleic 
acid (RNA) of approximately 15 200 nucleotides. This genome contains 10 different 
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genes in the order 3’NS1-NS2-N-P-M-SH-G-F-M2-L. Each gene encodes for a 
corresponding messenger RNA (mRNA) (Figure 2.2).  
The first 9 genes are separated by intergenic regions that vary in length from a single 
adenosine residue (N-P intergenic sequence) to 52 nucleotides (G-F intergenic 
sequence). The M2 and L genes, on the other hand, overlap by 68 nucleotides 
(Collins et al., 1986).  
 
Figure 2.2. The 3’ to 5’ negative-sense genomes of HRSV strain A2. The 
overlapping open reading frames (ORFs) of the M2 mRNA are illustrated over the 
M2 genes. Numbers beneath each map indicate nucleotide (nt) lengths; those of 
the extragenic leader (le), trailer (tr), and intergenic regions are underlined, and 
that of the HRSV gene overlap is in parentheses. Italicized numbers above each 
map indicate amino acid (aa) lengths (Straus, 2013).  
 Proteins: 2.1.3
HRSV mRNA encodes for 11 proteins (NS1, NS2, N, P, M, SH, G, F, M2-1, M2-2 and 
L).  
The G, F and SH proteins are envelope proteins, the M resides on the inside of the 
envelope, the N, P, L and M2-1 proteins are nucleocapsid proteins, M2-2 protein is a 
regulatory protein and NS1 and NS2 are non-structural proteins.  
Ø The HRSV G protein, a type II membrane protein formed by polymerization of 289 
to 299 amino-acids (aa) (depending on the virus strain), is the major attachment 
protein of HRSV (Levine et al., 1987; Ghildyal et al., 2005; Melero et al., 2016). 
This protein is also known for its role in infectivity and antigenicity of HRSV. 
Among all the HRSV proteins, the G protein is the most variable gene product 
between HRSV isolates. Antigenic differences of this protein have been used to 
classify HRSV isolates into two groups (A and B) (Melero et al., 2016).  
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Ø The HRSV F protein is a class 1 fusion protein, consisting of 574 aa, and it 
mediates binding of HRSV to cellular receptors and induces pH-independent 
fusion between the viral envelope and the cellular plasma membrane (Eckardt-
Michel et al., 2008).  
Ø The SH protein is a short type II transmembrane glycoprotein containing 64 to 65 
aa residues (Araujo et al., 2016). It has been shown that SH plays a role in fusion 
mediation (Heminway et al., 1994) and apoptosis inhibition in cell lines (Fuentes et 
al., 2007). 
Ø The M protein contains 256 aa residues. It is present between the outer envelope 
and inner ribonucleoproteins. It plays a role in virus assembly and budding 
(Bajorek et al., 2014).   
Ø NS1 and NS2 are non-structural proteins containing 139 and 122 aa residues 
respectively. These two proteins interfere strongly with host innate immunity by 
inhibiting IRF 1 and 3 signalling pathways (Ren et al., 2011). 
Ø The N protein contains 391 aa. This protein is tightly bound to the single-stranded 
RNA of the HRSV, forming a nuclease-resistant helical ribonucleoprotein complex, 
called nucleocapsid (Tawar et al., 2009). The N protein gene is the highly 
conserved gene in the HRSV genome (Zhang et al., 2009). Also, there is a strong 
interaction between the P protein and the N protein in the formation of the 
nucleocapsid (Slack & Easton, 1998).  
Ø The P protein contains 241 aa and is a phosphoprotein. This protein is known to 
confer stability to the L protein (Simabuco et al., 2011).  
Ø The L protein, containing 2165 aa, is an RNA-dependent RNA-polymerase that is 
involved in mRNA transcription and genome replication (Tremaglio et al., 2013). 
Ø The M2-1 protein, containing 194 aa, is an essential transcription processivity 
factor that prevents premature termination during transcription (Collins et al., 1996). 
It also acts as a transcription anti-terminator by enhancing the ability of the 
polymerase to read through transcription termination signals (Fearns & Collins, 
1999).  
Ø The M2-2 protein is a small protein of 90 aa residues. It is encoded by a second 
ORF in the M2 mRNA that overlaps the 5’-proximal M2-1 ORF (Collins et al., 
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1990). This protein is particularly known for its importance in the regulation of the 
viral RNA transcription and replication.  
 The Replication Cycle: 2.1.4
To initiate the replication cycle, HRSV has to bind first to a receptor on the host cell. 
In 1987, using mono-specific anti-G serum induced in rabbits, the G protein was 
demonstrated to be the HRSV attachment protein (Levine et al., 1987). Additionally, 
cellular glycosaminoglycans (GAG) appeared to be the main cellular attachment site 
of HRSV G protein. The most important GAG types for HRSV infection in HEp-2 cells 
are heparin sulphate and chondroitin sulphate B (Hallak, Collins, et al., 2000). The 
negative electrostatic charges on GAG chains provided by the sulphate groups are 
known to facilitate this binding process (Hallak, Spillmann, et al., 2000). Apart from 
GAG, the following surface molecules had been identified as potential HRSV 
receptors: CX3CR1 (Johnson et al., 2015), ICAM-1 (Arnold et al., 1995) and RhoA, 
which is also known to play a role in the syncytium formation (Gower et al., 2005). 
After attachment to the host cell, HRSV undergoes the process of entry, which is 
modulated by the fusion protein F. This protein mediates the fusion of the HRSV 
envelope with the host cell membrane in a pH-independent fashion (Zhao et al., 
2000). Several studies have suggested that the HRSV F protein undergoes 
conformational changes after binding to the host cell membrane. Its fusion peptide is 
then inserted into the cell membrane where its 2 main domains interact to form a 
stable core structure resulting in membrane apposition. Finally, the fusion pore opens 
and viral genetic material enters the host cell. The entry can also be mediated by 
endosomal membranes following clathrin-mediated endocytosis (Baker et al., 1999; 
Zhao et al., 2000; Sun et al., 2013).  
Genome transcription and replication occur concomitantly in the cytoplasm. Figure 
2.3 shows an overview of HRSV genome transcription and replication. It is known 
that the HRSV genome is bordered by two short extragenic regions: a 3’ leader 
region (Le) formed by 44 nucleotides and a 5’ trailer region (Tr) formed by 155 
nucleotides (Mink et al., 1991). The polymerase initiates transcription at position 3 of 
the Le promoter (Tremaglio et al., 2013) and transcription progresses along the 
length of the genome by a sequential termination-reinitiation (stop-start) mechanism. 
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This stop-start transcription is directed by gene start (GS) and gene end (GE) signals 
found at the upstream and downstream boundaries of each gene (Kuo et al., 1997). 
The GE also initiates the 3’-polyadenylation as the GS initiates the 5’-capping. 
Subgenomics mRNAs (which are polyadenylated at the 3’ end and capping at the 5’ 
end) are then released and translated into their corresponding viral proteins using the 
host cell machinery.  
 
Figure 2.3: Paramyxovirus RNA synthesis. Viral nucleocapsids, the templates for 
RNA synthesis, are shown as a linear array of N subunits (ovals), with 
arrowheads indicating the gene junctions. Note that N protein binds six 
nucleotides, resulting in complete encapsidation of the RNA if it has a chain 
length that is an even multiple of six. The viral polymerase (P-L) transcribes the 
genome template, starting at its 3’ end, to generate the positive leader RNA and 
the successive capped (meG-Cap) and polyadenylated (PolyA) mRNAs, by 
stopping and restarting at each junction. Once these primary transcripts have 
generated sufficient viral proteins, unassembled N (as a P-N complex) begins to 
assemble the nascent leader chain, and the coordinate assembly and synthesis 
of the RNA cause the polymerase to ignore the junctions, yielding the 
antigenome nucleocapsid (bottom). The P-L polymerase can also initiate RNA 
synthesis at the 3’ end of the antigenome in the absence of sufficient P-N; 
however, only a 5’ trailer RNA is made in this case. Note that positive leader RNA 
is not capped or polyadenylated and that genomic and antigenomic RNA never 
appear as naked RNA (Lamb & Parks., 2006).  
Replication, as with transcription, begins by the binding of the polymerase to the Le 
promoter. In this case however, it does not respond to GE and GS signals but 
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instead generates a full-length complementary positive-sense RNA (the antigenome) 
which will serve as a template for the synthesis of the viral negative-sense RNA 
genome. In its 3’ region, the antigenome has a complement of the trailer (TrC). The 
polymerase binds to a promoter in the TrC and initiates the synthesis of the viral 
genome (Cowton et al., 2006).  
Assembly and budding occur at the plasma membrane. It has been shown that the 
cytoskeleton plays a role in the transport of the ribonucleoprotein complex to the 
budding site (Santangelo & Bao, 2007) as well as in the optimization of HRSV 
budding and release (Shahriari et al., 2016). 
 HRSV Immunity and Pathology: 2.2
 Innate Immunity 2.2.1
Respiratory epithelial cells are recognized as initial targets of HRSV infection and as 
the first site for innate immune response activation (Bueno et al., 2008). As soon as 
HRSV contacts airway respiratory cells, it is recognized by toll-like receptors (TLR) 
present on the plasma membrane. Various TLR are involved in HRSV immunity. 
TLR4 plays the major role. Stimulation of TLR4 by HRSV F protein leads to activation 
of intracellular signalling pathway NF-kB and thus inflammatory cytokine production 
such as interleukin (IL)-6, IL-8 and IL-10 (Haeberle et al., 2002).  
It was shown that, compared to wild-type mice, TLR4-deficient mice were unable to 
mount an innate immune response to HRSV F protein and to clear infection (Kurt-
Jones et al., 2000). In addition, some studies have revealed that genetic 
polymorphisms of TLR4 genes can predict HRSV infection risk and disease severity 
(Zhu et al., 2015), and the TLR4 mutations Asp299Gly and Thr399Ile have been 
correlated with the gravity of HRSV infection in children (Tulic et al., 2007).  
In addition to TLR4 (Kurt-Jones et al., 2000), TLR3 (Rudd et al., 2006), TLR7 
(Schlender et al., 2005) and TLR2 (Murawski et al., 2009) can also activate immune 
responses upon HRSV recognition.  
Respiratory epithelial cells exposed to HRSV produce a broad range of pro-
inflammatory cytokines. Although CXC chemokines (particularly CXCL10 / interferon 
[IFN]-γ inducible protein [IP]-10 and CXCL8 / IL-8) are the most abundant 
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chemokines during HRSV infection. CC chemokines (CCL2 / monocyte chemotactic 
protein [MCP]-1 and CCL3 / macrophage inflammatory protein [MIP]-1α) are also 
present (McNamara et al., 2005). These chemokines act as chemo-attractants that 
guide the migration of cells of the immune system (neutrophils, monocytes, memory 
T cells, and eosinophils) from blood to infected tissues. These recruited cells 
contribute to the cytokine production (Jafri et al., 2004) which concurrently helps to 
contain HRSV infection, but also enhance tissue damage (Janssen et al., 2007). 
Many studies have shown that by reducing pro-inflammatory cytokine production, 
lung injury was considerably decreased (Foronjy et al., 2014; Ren et al., 2016; 
Schuijs et al., 2016).  
Another important first line defence is airway mucus production. Mucus is secreted 
by epithelial goblet cells. Its main role is to protect respiratory airways from injury due 
to its viscosity and through mucocilliary clearance. Even though airway mucus 
production is considered a part of innate defence, it can actually worsen the disease 
by obstructing respiratory airways when it is secreted abundantly (Johnson et al., 
2007).  
 The Role of Dendritic Cells in the Link of Innate and Adaptive Immunity 2.2.2
Dendritic cells (DC) are antigen-presenting cells (APC) of the mammalian immune 
system. They play a key role in the regulation of the immune response by connecting 
innate and adaptive immunity (Kim & Lee, 2014). There are 2 main lineages of DC: 
conventional CD11c+ DC (cDC; previously called myeloid DC) and 
CD11clow/mPDCA-1+ plasmacytoid DC (pDC) (Wikstrom & Stumbles, 2007; Satpathy 
et al., 2012).  
In the mouse lung, there are two major cDC populations: CD11c+ / CD103− / 
CD11bhigh cDC (CD11bhi cDC) are located in the lung parenchyma and 
CD11c+/CD103+/CD11blow cDC (CD103+ cDC) are located in the basal lamina of the 
airway epithelium and spread their dendrites all over the epithelium (Lukens et al., 
2009).  
After their maturation, cDC activate adaptive immune system cells (Manicassamy & 
Pulendran, 2011). CD103+ cDC are important for the induction of CD8+ T-cell 
responses, while CD11bhi cDC mainly activates naïve CD4+ T cells (Lukens et al., 
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2009). cDC in lymph nodes present HRSV-antigen to CD8+ and CD4+ T cells via 
Major histocompatibility complex (MHC)-I and MHC-II respectively (Lukens et al., 
2009). It is known that MHC-I molecules present endogenous antigen and MHC-II 
exogenous ones (Ryan & Cobb, 2012). 
Lung pDC activate the antiviral function of other cells by producing type I IFN, when 
the receptor TLR7 recognizes the antigen (Johnson et al., 2011; Garg et al., 2012). It 
has been shown that pDC play a role in the limitation of lung pathology during acute 
HRSV infection by limiting T helper (Th) 2 cytokine production (Smit et al., 2006, 
2008).  
 Adaptive Immunity 2.2.3
2.2.3.1 T Cell Response 
Once activated by infected DC, CD8 T cells migrate from the lymph nodes to the site 
of infection. This migration is governed by the chemokine CXCL10/CXCR3 (Lindell et 
al., 2008) and the inhibition of the production of this chemokine can lead to an 
exacerbated HRSV disease. CD8+ T cells control the infection by cytokine 
production and by lysing the infected cells.  
Cytotoxic T lymphocytes (CTL) can lyse infected cells by two ways. The first is the 
perforin-granzyme pathway. When the CTL receptor binds to the target cell, CTL 
releases perforin and granzyme proteins. The perforin protein binds to the target cell 
and forms a pore by polymerization. The granzyme protein then penetrates into the 
target cell and induces nucleic acid fragmentation (Kägi et al., 1996; Fan & Zhang, 
2005). The second pathway is the Fas Ligand pathway. Fas ligand is a type II 
transmembrane protein that can cause cell apoptosis when binding to its receptor 
(Fas). It has been shown that ligation of Fas causes assembly of an intracellular 
death inducing signalling complex through the activation of the cysteine protease 
caspase-8 and activation of the caspase cascade (Strasser et al., 2009; van den 
Berg et al., 2011). 
Th cells, also known as CD4+ T cells, are implicated in HRSV immunity as well as in 
the immune-mediated pathology during HRSV infection (Johnson et al., 2007). A 
process of activation occurs when a naïve Th cell interacts with a DC. This process is 
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performed in three different signals. The first signal is the recognition of the antigen 
(carried by the MHC II protein of the DC) by the Th cell receptor (Janeway CA et al., 
2001). The second signal involves the interaction between the DC molecules CD80 
and CD86 which bind to CD28 on the Th cell (Linsley et al., 1990; Thauland et al., 
2014). The third signal is mediated by cytokines binding to the Th cell receptor. 
Depending on the cytokine environment, Th cells proliferate either into Th1 cells or 
Th2 cells. IFN-γ drives Th1 proliferation as Th2 proliferation is driven by IL-4 (Tanaka 
et al., 2000; Wurster et al., 2002; Zhu, 2015). It has been shown that a Th2-mediated 
immune response to HRSV infection is associated with mucus production and airway 
hyperactivity. Comparing the ratio of IL-4 to IFN-γ from infants with HRSV acute 
bronchiolitis to those with HRSV upper respiratory tract infection (URTI), Legg et al. 
(2003) found that this ratio was markedly higher in the first group than in the second 
one. Thus, Th2 cytokines can be considered as makers of HRSV severe disease.  
2.2.3.2 B Cell Response and Antibodies 
Naïve B cells are activated by two different mechanisms: the T cell-dependent 
activation and the T cell-independent activation (Parker, 1993; Hess et al., 2013). In 
HRSV immunity, naïve B cells are activated through the T cell-dependent pathway 
(Varga & Braciale, 2013). These activated B cells will produce antibodies. Even 
though HRSV infection can induce antibody responses against several viral antigens, 
it has been shown that only the two major surface glycoproteins, F and G, induce 
antibodies that have a major role in protection (Groothuis, 1994). Although antibody 
responses are vital for protection against HRSV infection, cellular immune responses 
may have a greater role in virus clearance (Oshansky et al., 2009).  
 HRSV Mechanisms of Immune Escape (Modulation) 2.2.4
HRSV NS1 and NS2 proteins can inhibit type I IFN production and signalling (Spann 
et al., 2004; Ramaswamy et al., 2006). 
HRSV G protein is known to bind neutralizing antibodies, thereby preventing 
neutralization or opsonization of viral particles. G protein can also serve as a soluble 
chemokine receptor agonist (Varga & Braciale, 2013).  
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 Pathology 2.2.5
By assessing the HRSV-specific immune response in humanized mice (mice with a 
human immune system) with functional human CD4+ T and B cells, Sharma et al. 
(2016) proved that HRSV infection induces the following pathological features: 
peribronchiolar inflammation with neutrophil predominance in the bronchiolar lavage 
fluid and enhanced airway mucus production. Comparing epithelial cell pathology 
from 250 autopsies of young children with ARI including HRSV infection, 
adenoviruses (ADV), influenza virus and PIV, Zinserling (1972) noticed that HRSV 
was causing the greatest degree of bronchiolar involvement. Many researchers 
agree that HRSV can lead to the formation of multi-nucleated polypoid epithelial cells 
casting off into the airway lumen (Shedden & Emery, 1965; Delage et al., 1984; 
Neilson & Yunis, 1990).  
 Epidemiology 2.3
 HRSV Burden: 2.3.1
2.3.1.1 Worldwide and Western Countries 
HRSV is the most common cause of respiratory tract infection in children worldwide 
(Bont et al., 2016; Fall et al., 2016; Gamino-Arroyo et al., 2016). By estimating 
incidence for industrialized and developing countries for 2005, and summing these 
estimates, Nair et al. (2010) has indicated that during that year, 33.8 million new 
cases of non-severe HRSV-associated infection occurred globally in children younger 
than 5 years. Of these, 96% arose from developing countries (more than 90% of the 
world’s population aged younger than 5 years live in developing countries). Moreover, 
the author indicated that the 2005 estimated global incidence of severe HRSV-
associated disease in children younger than 5 years was approximately 3.4 million 
cases, among which 91% occurred in developing countries. Furthermore, by 
combining data from 25 published and 6 unpublished studies, the author estimated 
the number of deaths due to HRSV-associated severe LRTI in children admitted to 
hospital. He found that 66 000 to 155 000 children younger than 5 years died in 2005 
as a result of HRSV-associated severe LRTI.  
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HRSV prevalence was determined by Nolan et al. (2015) in a cohort of children aged 
from 6 months to 10 years with influenza-like illness who were enrolled in a 
randomized clinical trial of 2 pandemic influenza virus H1N1 vaccines conducted in 
17 centres all over the world. The authors reported an overall HRSV prevalence of 
9.7%. 
Stein et al. (2016) has also revealed, through a meta-analysis that included 55 
studies from 32 countries all over the world, the burden of severe HRSV infection. 
The author mentioned that in children younger than 5 years the global HRSV ARI 
hospitalization estimate was reported to be 4.37 per 1 000 children per year. This 
estimate was 19.19 per 1 000 among children younger than 1 year and 20.01 per 
1 000 among children younger than 6 months, while among premature children under 
1 year it was 63.85 per 1 000 children. Among children younger than 5 years, it was 
6.21 per 1 000, 6.60 per 1 000 among those younger than 1 year and 1.04 per 1 000 
among preterm children younger than 1 year.  
In a systematic review done in 2016 by Bont et al. (2016), the author analysed the 
burden of severe HRSV infection among infants and children in Western countries by 
collecting data from 98 studies published between January the 1st 1995 and 
December the 31st 2015. The data showed that HRSV was associated with 12-63% 
of all ARI and 19-81% of viral ARI leading to hospitalization in children. It was 
concluded that in comparison to influenza virus, HRSV lead up to 16 times more 
hospitalizations and emergency department visits in children younger than 5 years.  
In the United States of America (USA), HRSV has led to an average of 2.1 million 
outpatient visits among children younger than 5 years old and 57 527 hospitalizations 
among those children in 2009 (Hall et al., 2009).  
2.3.1.2 Africa 
The epidemiology of HRSV ARI across Africa varies from country to country, as 
shown in Table 1.  
HRSV prevalence in children under 5 years in Kenya is around 17% (Bigogo et al., 
2013; Nyawanda et al., 2016). Bigogo et al. (2013) has reported incidence rates of 
severe HRSV ARI in Kenya among infants under 1 year of age and among children 
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younger than 5 years. In the first group, the HRSV ARI incidence rate was 62.8 to 
86.9 episodes per 1 000 person-years while, in the second group, this incidence rate 
was 23.7 to 26.9 episodes per 1 000 person-years. Emukule et al. (2014), on the 
other hand, analysed the HRSV ARI hospitalization incidence rate at two health 
facilities in western Kenya. The author found an incidence rate of 5.2 per 1 000 
children younger than 5 years.  
In South Africa, many scientists have worked on HRSV. Among children younger 
than 5 years and suffering from severe ARI, Pretorius et al. (2016) reported a very 
high significant attributable factor for HRSV (>90%), with an adjusted prevalence of 
22.4%. Kyeyagalire et al. (2014) estimated the HRSV-associated all respiratory 
hospitalization rate among children younger than 1 year to be 7 601 per 100 000 
person-years. Tempia et al. (2014) found in children younger than 5 years of age, the 
mean annual number of HRSV-associated all respiratory deaths was 10 per 100 000 
person-years.  
Table 2.1 HRSV prevalence in Africa 
Reference Country Prevalence Cohort 
Pretorius et al. (2016) South Africa 10.7% (N= 5743) Outpatients and 
inpatients 
Bigogo et al. (2013) Kenya 17% (N=2050) Outpatients and 
inpatients 
Fodha et al. (2004) Tunisia 21.6% (N= 815) Inpatients 
Ouédraogo et al. (2014) Burkina Faso 11.9% (N= 209) Inpatients and 
outpatients 
Loscertales et al. (2002) Mozambique 9.8% (N= 1172) Inpatients and 
outpatients 
Kwofie et al. (2012) Ghana 14.1% (N= 128) Inpatients 
Weber et al. (2002) Gambia 8.7% (N= 4799) Inpatients 
 
 HRSV and Risk for ARI to be Diagnosed as LRTI  2.3.2
Most cases of HRSV ARI are presented as URTI. In some cases however, URTI can 
extend and lead to LRTI. Certain factors are known to increase the risk of severe 
HRSV ARI. The major risk factors include: premature birth (Helfrich et al., 2015), low 
birthweight (Parejo et al., 2016), increased exposure (day-care attendance, siblings 
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younger than 5 years of age, admission to the hospital during HRSV season) 
(Anderson et al., 1988), passive smoking (Gurkan et al., 2000; DiFranza et al., 2012), 
family history of atopy (Trefny et al., 2000), low parental education and socio-
economic income (Glezen et al., 1981), indoor air pollution (Al-Sonboli et al., 2006), 
no breastfeeding (Nishimura et al., 2009), chronic lung disease (Paes et al., 2016), 
congenital heart disease (Friedman et al., 2017), neuromuscular diseases(Resch et 
al., 2009) and primary immunodeficiency disorders (Lanari et al., 2014). 
In 2015, Shi et al. (2015) carried out a systematic review with meta-analysis aimed to 
identify risk factors for HRSV-associated LRTI in children younger than 5 years of 
age. The author included 20 studies with good quality that investigated 18 risk factors 
of HRSV-associated LRTI, among which 8 were significantly associated. The meta-
estimates of their odds ratios (OR) were as following: prematurity - 1.96 (95% 
confidence interval [CI] 1.44-2.67), low birthweight - 1.91 (95% CI 1.45-2.53), male 
gender - 1.23 (95% CI 1.13-1.33), having siblings - 1.60 (95% CI 1.32-1.95), 
maternal smoking - 1.36 (95% CI 1.24-1.50), history of atopy - 1.47 (95% CI 1.16-
1.87), no breastfeeding - 2.24 (95% CI 1.56-3.20) and crowding - 1.94 (95% CI 1.29-
2.93).  
 HRSV and Viral Co-Infection 2.3.3
The progress of molecular diagnostic tools for the detection of respiratory viruses has 
provided insight into the viral respiratory dynamics during respiratory infection. 
Hence, some researchers have focused their attention on the weight of viral co-
infection during ARI.  
Even though epidemiologic data had shown that when the rate of HRSV infection is 
high, the influenza virus infection rate tends to be low (and vice versa) (Wang et al., 
2013), Mazur et al. (2017) has reported that HRSV-influenza virus co-infection 
increases the odds for prolonged hospitalization when compared to HRSV mono-
infection. The author also reported that HRSV-ADV co-infection had a 3.4 increased 
odds of life-threatening disease compared with RSV mono-infection. However, the 
role of HMPV in severe HRSV infection is still controversial. While Van Woensel et al. 
(2006) reported that HMPV is not frequent in severe HRSV LRTI, McNamara et al. 
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(2007) suggested that HRSV-HMPV co-infection is clinically symptomatic for longer 
than RSV mono-infection.  
Other viruses, such as HRV, CoV, BoC, PIV and EV are also implicated in HRSV co-
infection, but the direction of this relationship is mostly unclear.  
 Clinical Features and Diagnosis: 2.4
 Clinical Features:  2.4.1
HRSV transmission is through direct or close contact with contaminated secretions. 
The incubation period is 2 to 8 days and the period of viral shedding is usually 3 to 8 
days, but it may continue for as long as 3 to 4 weeks (American Academy of 
Pediatrics [AAP], 2009). 
In infants and children, HRSV infection can manifest either as URTI (rhinitis, 
pharyngitis, acute bronchitis) or LRTI (bronchiolitis, pneumonia) (Glezen et al., 1986).  
HRSV URTI usually occurs in older children (mostly as reinfection) and can manifest 
as cough, coryza, rhinorrhoea and conjunctivitis, although ears (Kristjansson et al., 
2010) and sinuses(Ramadan et al., 1997) can also be affected.  
LRTI is characterized by signs of increased respiratory effort (tachypnea, nasal 
flaring, chest retraction), wheezing, shortness of breath and rales. Severe HRSV 
LRTI can lead to respiratory failure and even death (Geoghegan et al., 2016).  
Many studies have reported a correlation between HRSV LRTI and subsequent 
respiratory function impairment characterized by recurrent wheezing and asthma 
later in life (Fauroux et al., 2017; Kabego & Beer, 2017). Moreover, it was shown that 
prevention of HRSV LRTI using palivizumab has the effect of decreasing the odds of 
recurrent wheezing late in childhood (Simoes et al., 2007).  
 Laboratory Diagnosis: 2.4.2
The laboratory diagnosis of HRSV is made by analysing respiratory secretions. 
Different types of sample types, such as nasopharyngeal aspirates and swabs, as 
well as nasal and throat swabs, can be used (Gray et al., 1968; Stensballe et al., 
2002). 
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HRSV culture is traditionally known as the gold standard for HRSV laboratory 
diagnosis (Popow-Kraupp & Aberle, 2011). However, culture can be 
disadvantageous due to virus lability, the time taken to produce results and the 
storage of specimens at cold temperatures (Tregoning & Schwarze, 2010). HEp-2, 
Vero, HeLa, and A549 cells are the most sensitive cell lines for primary isolation 
(Mahony, 2008; Corry et al., 2016). 
Diagnosis can be made more rapidly by direct immunofluorescence assay (DFA) for 
viral antigen detection or antigen-capture enzyme immunoassay (EIA). In the DFA, a 
primary antibody is linked to a fluorophore that will recognize the HRSV antigen 
within the sample. A wavelength of light is produced during the reaction and is 
visualized by fluorescent microscopy (White et al., 1988). In the EIA, the sample is 
added to a microplate coated with immobilized antibodies that bind to the HRSV 
antigen. A secondary antibody linked to an enzyme is then added, followed by the 
addition of a substrate, which is then converted to a detectable form through colour 
change. The reaction plate is read spectrophotometrically at a specific wavelength 
(Wren et al., 1990) and the optical density is proportional to the concentration of the 
antigen in the sample.  
Nucleic acid assays are the most sensitive and specific methods for the detection of 
HRSV (Falsey et al., 2003). Of the different nucleic acid amplification techniques, 
reverse transcription polymerase chain reaction (RT-PCR) is the most frequently 
used (Popow-Kraupp & Aberle, 2011).  
 Prevention and Treatment of HRSV: 2.5
 Prevention 2.5.1
HRSV has a very high basic reproduction number (the average number of uninfected 
people who can become infected from one infectious person), which is estimated to 
be between 5 and 25 (Weber et al., 2001). This virus is one of the major nosocomial 
hazards in paediatrics wards. IPC measures and passive immunoprophylaxis of high-
risk individuals can be helpful to prevent HRSV infection.  
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2.5.1.1 Infection Control:  
In the community, HRSV infection can be reduced by hand hygiene and avoiding 
settings with increased risk of exposure, such as childcare centres.  
In health settings, the following practices may reduce HRSV infection: hand hygiene 
(Weedon et al., 2013), the use of personal protective equipment (gowns, gloves and 
goggles) by staff (French et al., 2016), isolating or cohorting infants with HRSV 
infection (Groothuis et al., 2008), excluding visitors with current respiratory tract 
infections, excluding staff with respiratory tract illness or HRSV infection from caring 
for susceptible infants and limiting young sibling visitation during the HRSV season 
(AAP, 2009).  
2.5.1.2 Passive Immunoprophylaxis: 
Presently, palivizumab is the only available option for HRSV prophylaxis. However, 
due to its high cost and restricted clinical benefits, its use has been limited to a group 
of high-risk infants (Rezaee et al., 2017). Wegzyn et al. (2014) conducted a 
systematic review and summarized the evidence of the effectiveness of palivizumab. 
The author reported that there were low HRSV-related hospitalization rates in 
palivizumab recipients when compared to placebo with an OR of 0.41. In addition, 
among palivizumab-prophylaxed subjects, rates of intensive care unit admission and 
mechanical ventilation from HRSV hospitalization were also low.  
2.5.1.3 Vaccines:  
There is no licensed vaccine available yet for HRSV infection. However, many 
vaccine candidates are currently being evaluated for their effectiveness and safety 
(Glenn et al., 2013, 2016; Malkin et al., 2013; Taylor et al., 2015). The main 
strategies of HRSV vaccine development are: attenuating the virus or using 
recombinant technology to present viral antigens.  
 Treatment: 2.5.2
Here, the focus will mostly be on the treatment of RSV bronchiolitis, which has a 
considerable burden in child health.  
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2.5.2.1 Supportive Care: 
Hydration (fluid management) and oxygenation remain the cornerstones of 
bronchiolitis clinical management (Mazur et al., 2015). According to 
recommendations of the American Academy of Paediatrics (AAP), supplemental 
oxygen is recommended if oxyhaemoglobin saturation falls persistently below 90% in 
previously healthy infants. Moreover, the AAP recommends the administration of fluid 
to children suffering from bronchiolitis, depending on their ability, orally or through a 
gastric tube or intravenous catheter (American Academy of Pediatrics, 2006; Ralston 
et al., 2014).  
The AAP recommends not using the following therapeutics options: corticosteroids 
(strong recommendation), epinephrine (strong recommendation), albuterol or 
salbutamol (strong recommendation), chest physiotherapy (moderate 
recommendation) and antibacterial drugs (unless a concomitant bacterial infection is 
present or strongly suspected) (strong recommendation). However, nebulized 
hypertonic saline may be administered by the clinician to infants and children with 
bronchiolitis.  
Other therapeutic options are currently being evaluated for their effectiveness in the 
management of HRSV bronchiolitis. These include exogenous surfactants (Jat & 
Chawla, 2015) and a helium/oxygen mixture (heliox) (Seliem & Sultan, 2017). 
2.5.2.2 Antiviral Intervention: 
Ribavirin, a purine analogue, is an antiviral medication approved by the USA Food 
and Drug Administration (FDA) for the treatment of HRSV bronchiolitis (Marcelin et 
al., 2014). However, the high cost, difficulty to administer make the use thereof 
controversial (Wright et al., 2008). Therefore, the AAP does not recommend its 
routine use in children with bronchiolitis (Turner et al., 2014). 
 Summary 2.6
HRSV, a single-stranded RNA virus, is a major cause of ARI in children worldwide 
and is responsible of a substantial number of children deaths each year.  There is 
neither a licensed vaccine to prevent HRSV infection nor an effective drug to treat it. 
However, in community as well as in hospital settings, HRSV can be contained 
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during the HRSV period and even prevented when its epidemiology is well known. 
This study will provide much needed information on HRSV and ARI epidemiology in 
DRC which can be used to improve the healthcare system. 
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CHAPTER 3: MATERIALS AND METHODS 
 Ethical Aspects: 3.1
Ethics approval was obtained from the Health Research Ethics Committee of 
Stellenbosch University (Appendix 1) and from the Ethics Committee of the Catholic 
University of Bukavu (Appendices 2 and 3).  
 Study Design 3.2
An analytical cross-sectional study design was used and its main purposes were: 
Ø To determine the prevalence of HRSV ARI and non-HRSV ARI in children under 
the age of 5 years.  
Ø To investigate the relationship between independent variables (socio-economic 
factors, clinical data and RT-PCR results) and the dependent variable (ARI).  
 Study Settings 3.3
Bukavu is a city in the eastern region of DRC. It is the capital of the South Kivu 
province with an estimated population of 870 954 in 2003 (Yogolelo, 2013). 
PGHB is a main healthcare facility of Bukavu. It also serves as the health reference 
centre for the province of South Kivu and as the teaching hospital of the Catholic 
University of Bukavu. It has 385 beds with 6 400 admissions and 4 900 outpatients 
per year.  
 Participants 3.4
In a consecutive manner, 146 patients visiting the PGHB for ARI were prospectively 
recruited between August and December 2016.  
Inclusion criteria for the study were all children under 5 years, who were experiencing 
an episode of ARI within the week prior to visiting the paediatric department of PGHB 
either as an outpatient or an inpatient; regardless of gender, provenance, religion and 
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social status. Before enrolling a participant, the parent or guardian had to sign the 
consent form after reading and understanding it properly.  
Exclusion criteria were children older than 5 years and those who visited the PGHB 
for other symptoms not relating to ARI.   
 Variables 3.5
A clinical examination, performed by a paediatrician and a study questionnaire 
(Appendix 5) allowed the collection of clinical data and socio-demographic 
characteristics of the participants.  
 Outcome 3.5.1
The outcome of this study was ARI. It was classified in two groups: URTI and LRTI. 
Participants with bronchiolitis or pneumonia belonged to the LRTI group. Bronchiolitis 
was defined as a set of clinical symptoms occurring in children less than 2 years of 
age, characterized by upper respiratory symptoms (rhinorrhoea, cough) followed by 
wheezing. Pneumonia was defined as the presence of signs of LRTI (breathing fast, 
lower chest indrawing, crackles, fever) and characteristic signs of pneumonia on 
chest radiography. 
Children who presented with cough, nasal secretion or difficulties in breathing, but no 
other signs of LRTI, were considered as suffering from URTI. These children had one 
of the following diagnoses: rhinitis, laryngitis, otitis or bronchitis. LRTI and URTI were 
mutually exclusive.   
 Explanatory Variables or Predictors 3.5.2
Baseline explanatory or independent variables included:  
Ø Socio-demographic characteristics: age, gender, weight, settings (urban or 
rural), income level, maternal education, number of siblings in the household, 
alcohol exposure during pregnancy, cigarette and cooking smoke exposure. 
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Ø Medical features:  
¯ Medical history: birthweight, specific gestational age, history of neonatology 
stay, as well as oxygen therapy, family history of atopy 
¯ Clinical findings: nutritional status (malnutrition), antibiotic use before visit, 
symptoms duration, immunization status, exclusive breastfeeding, and 
admission.  
¯ Management: antibiotic use, oxygen therapy, nasogastric intubation. 
Ø RT-PCR result. The following viruses were screened for: HRSV A and B, 
influenza virus A and B, HRV A/B/C, CoV OC43 and CoV 229E/NL63, PIV 1, 2, 3 
and 4, HMPV, HBoV, ADV and EV. Mono-infection was defined as the detection of 
only one virus, while co-infection was defined as the detection of at least two 
viruses.  
According to their household income, participants were classified in 3 groups: low 
income (< 100 USD per month), middle income (100 to 500 USD per month) and 
high income (>500 USD per month). Moreover, they were classified according to the 
level of education of their mother in 4 groups: illiterate (can’t read and write), primary 
(1 to 6 years at primary school), secondary (1 to 6 years at secondary school) and 
university (≥ 1 year at university). Cigarette smoke exposure was defined as the 
presence of smokers in the household. Cooking smoke exposure was considered 
when biomass fuel was used for cooking in the house. Participants were regarded as 
being exposed to alcohol during pregnancy if their mothers were drinking any kind of 
alcoholic beverage while pregnant. Malnutrition was defined as a weight-for-age z-
score ≤ 2. The z-score was calculated using the WHO anthro software version 3.2.2. 
All children born before 37 weeks gestational age were considered to be premature; 
children who had weighed less than 2.5 kg at birth were considered having a low 
birthweight. Exclusive breastfeeding was defined by the number of months that 
children were receiving only breastfeeding. There was a family history of atopy when 
the mother, father or sibling(s) reported ever having had asthma or atopy (allergic 
rhinitis or eczema). All the children who received any kind of treatment for at least 24 
hours in a neonatology care unit had a neonatology stay, among where some 
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received oxygen as part of their treatment. The investigator checked for immunization 
status of the participants according to the DRC health ministry (Miso et al., 2014). 
 Procedures 3.6
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Workflow diagram of the viral identification process  
 Specimen Collection, Storage and Transfer 3.6.1
a. Materials:  
Ø Swabs flocked paediatric 100MM B/Point Dry Tube ST (Lasec, Cape Town).  
Ø Tube Universal Transport Media (UTM) 16X100MM 3 ml (Lasec, Cape Town).  
Ø 2.0 ml graduated tube with Flat Top Cap (Whitehead Scientific, Cape Town)  
Ø 100-1 000 µl standard Tip Blue (Whitehead Scientific, Cape Town)  
Ø Sterile gloves, a paper surgical mask, a marker, a biohazard bag, facial tissues, 
eye protection, a vortex machine, a pipette, a cartoon ruler.   
Patient 
Sample 
Viral DNA/RNA 
PCR product 
Separated DNA 
fragment 
First-strand cDNA 
Sample collection 
RNA extraction 
Agarose gel electrophoresis 
Reverse transcription  
Multiplex PCR 
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b. Methods:  
The parent or guardian was fully informed about the procedure that was to take place. 
One assistant restrained the child’s arms and another his head.  
The distance between the base of the nose and ear loop of the child was measured 
with a disposable cartoon ruler. With a marker, the investigator marked the depth of 
the insertion of the swab, which was the half distance of the ear loop-base nose 
distance. The child’s head was tilted to a 70° angle and the flocked swab was 
inserted horizontally in one of the two nostrils until it reached the nasopharynx. Once 
there, it was left for a few seconds (2 to 3 seconds), pulled out with a rotating motion 
and inserted into a tube containing 3 ml UTM. The tube was transported to the 
laboratory on wet ice; it was mixed thoroughly by a vortex, the swab was removed, 
the specimen was placed into two 1.5 ml tubes and stored at -70°C.  
After the collection period, all the samples were sent on dry ice by DHL Express to 
the Tygerberg Virology Laboratory in Cape Town, South Africa. For that purpose, the 
investigator applied for a South African biological material import permit (Appendix 6), 
as well as a biological export permit from DRC (Appendix 7). 
 Nucleic Acid Extraction:  3.6.2
a. Materials:  
Viral nucleic acid was extracted from respiratory swab samples using the QIAamp 
cador Pathogen Mini Kit (Whitehead Scientific, Cape Town) according to the 
manufacturer’s instructions with a few modifications. This kit contains: 
Ø QIAamp Mini Columns  
Ø Collection Tubes (2 ml)  
Ø Buffer VXL  
Ø Buffer ACB (concentrate)  
Ø QIAGEN® Proteinase K  
Ø Carrier RNA (poly A)  
Ø Buffer AW1 (concentrate)  
Ø Buffer AW2 (concentrate)  
Ø Buffer AVE  
Ø Quick-Start Protocol  
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Buffer ACB, Buffer AW1 and Buffer AW2 were supplied as concentrates. Before 
using, 8 ml of isopropanol was added to 12 ml of Buffer ACB, 25 ml of 96% ethanol 
to 19 ml of AW1 and 40 ml of 96% ethanol to 17 ml of AW2.  
b. Methods:  
In brief, the process was as follows: 20 µl of proteinase K (digest proteins, which 
usually contaminate nucleic acid preparations) was pipetted into a 2 ml 
microcentrifuge tube. 200 µl of the sample was added to the tube. To enhance the 
lysis of the sample, 100 µl of Buffer of VXL containing 1 µl of carrier RNA was added 
and the solution was mixed by pulse-vortexing. The 2 ml tube was incubated at 20-
25°C for 15 minutes and briefly centrifuged. 350 µl of Buffer ACB (adjusts the binding 
conditions for the co-purification of DNA and RNA) was added to the sample and 
mixed thoroughly by pulse-vortexing. The 2 ml tube was briefly centrifuged. The 
lysate was transferred to the QIAamp Mini column placed in a 2 ml collection tube 
and then centrifuged at 8 000 rpm for 1 minute. The mini column was placed into a 
clean 2 ml collection tube. 600 µl Buffer AW1 was added into the QIAamp Mini 
column and centrifuged at 8 000 rpm for 1 minute. The QIAamp Mini column was 
placed in a clean 2 ml collection tube. Buffer AW2 was added into the QIAamp Mini 
column and centrifuged at 8 000 rpm for 1 minute. The QIAamp Mini column was 
placed in a clean 2 ml collection tube. The 2 ml collection tube was centrifuged at 
13 200 rpm for 3 minutes. The QIAamp Mini column was placed in a clean 1.5 ml 
microcentrifuge tube. 40 µl Buffer AVE (an elution buffer) was added to the centre of 
the membrane, the tube was incubated at room temperature (15-25°C) and 
centrifuged at 13 200 for 1 minute.  
After extraction, the nucleic acid concentration of each sample was measured on a 
NanoDrop spectrophotometer ND1000 (NanoDrop Technologies, USA) 
 Complementary DNA  3.6.3
RNA viruses and subtypes were analysed using complementary DNA (cDNA).  
a. Materials: 
RNA samples were reverse-transcribed into cDNA using RevertAid First Strand 
cDNA Synthesis Kit (Thermofisher Scientific, Cape Town). This kit contains random 
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hexamers, nuclease-free water, Revert Aid Premium Reverse Transcriptase enzyme, 
ribolock, dNTP mix and 5x RT Buffer. 
b. Methods: 
In brief, cDNA was performed as follows: after putting 8 µl of the sample into a 0.2 ml 
Quality Scientific Plastics (QSP) PCR tube, 2 master mix solutions were successively 
added. The first contains: 1 µl of random hexamers and 3 µl nuclease-free water. 
The second contains: 4 µl of 5XRT buffer, 1 µl of Ribolock, 2 µl of dNTP mix and 1 µl 
of Revert Aid Premium reverse transcriptase. cDNA synthesis was then done on a 
Gene Amp PCR system 9700. The reverse-transcription was initiated with an 
incubation of 5 minutes at 25°C and continued with a 60 minutes incubation at 42°C 
and ending with a 5 minute incubation at 70°C.  
 PCR:  3.6.4
a. Materials: 
cDNA was screened for 15 viruses using the Seeplex RV15 Ace Detection kit 
(supplied by Inqaba Biotechnical Industries). This kit contains: 
Ø Positive control 
Ø Negative control 
Ø 5XRV15 Ace 
Ø Multiplex Master mix 
Ø 8-Mop solution 
b. Methods: 
In brief, a master mix containing 4 µl of 5XRV15 Ace, 10 µl of 2X Multiplex Master 
mix, 3 µl 8-Mop solution and 3 µl of the sample was prepared in a 0.2 ml PCR tube, 
mixed and briefly centrifuge. Amplification reaction was performed on a Gene Amp 
PCR system 9700 using the PCR protocol listed in Table 3.1. A positive and negative 
control was included in each run. 
Stellenbosch University  https://scholar.sun.ac.za
 
28 
Table 3.1 Seeplex RV15 ACE PCR reaction program 
Step	 No of cycles	 Temperature	 Duration	
Initiation	 1	 94°C	 15 minutes	
Denaturation	  94°C	 0.5 minutes	
Annealing	 40	 60°C	 1.5 minutes	
Elongation	  72°C	 1.5 minutes	
Final elongation	 1	 72°C	 10 minutes	
 
 Visualization of PCR Products 3.6.5
Agarose gel electrophoresis was used to separate PCR products according to 
Sambrook & Russell (2001) with slight modifications.  
a. Materials: 
Buffers and solutions: 
Ø 2% Agarose solution 
Ø TAE (Tris base, acetic acid and EDTA) was used as the electrophoresis buffer. 
A 1X TAE working solution was prepared by mixing 20 ml of 50X TAE (Bio 
Basic Canada Inc) and 980 ml of water. 
Ø Gel loading buffer: GeneDirex® Novel juice (Biocom Biotech, Cape Town) 
Nucleic acids and Oligonucleotides: 
Ø PCR product 
Ø Positive and negative controls (provided with Seeplex RV15 Kit) 
Ø DNA molecular weight markers (provided with Seeplex RV15 Kit) 
Special equipment:  
Ø Horizontal gel electrophoresis apparatus 
Ø Gel combs and rubber gaskets (end gates) 
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Ø Basin with cold water  
Ø Microwave oven 
Ø Power supply device: BG Power6000 electrophoresis system (BayGene®, 
China) 
Ø Lab rotator (Digisystem laboratory instruments Inc. Taiwan) 
Ø UVITEC computer 
b. Methods: 
Preparing the gel: 
2 g of Lonza SeaKem® LE agarose (Whitehead Scientific, Cape Town) were 
dissolved in 100 ml 1X TAE and melted in a microwave oven for 3 minutes. Melted 
agarose was then cooled in a basin containing cold water before pouring it onto a 
horizontal gel electrophoresis apparatus (care was taken to make sure that the comb 
and rubber gaskets were placed). All bubbles on the surface of the agarose were 
removed and the gel was allowed to cool. After approximately 20 to 30 minutes, the 
gel was solidified and became slightly opaque. End gates were removed and we 
submerged the gel by adding 1X TAE buffer to cover the gel by about 0.5 cm. The 
comb was carefully removed by lifting it gently at one end.  
Loading and running the gel:  
5 µl of the PCR product, 5 µl of molecular markers, 2 µl of the positive control and 
2 µl of the negative control were each mixed with 1 µl of novel juice and loaded into 
individual wells with a gel loading tip and a P-20 Pipette. Once the loading was done, 
the cover was placed on the gel apparatus and leads were connected (the negative 
lead is at the end of the gel containing the wells) to the power supplier. The gel was 
run at 60 volts for 40 minutes and gently shaken on a lab rotator. 
Visualization of PCR products:  
The gel was examined using an UVITEC computer by regulating the scale under 
white light and visualizing bands under the transilluminator. 
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Table 3.2 Amplification information 
Set A Size (bp) Target gene 
Internal control 850 CesA3 
ADV 534 Major core protein 
CoV 229E/NL63 375 Spike 
PIV 2 264 HN 
PIV 3 189 F 
PIV 1 153 HN 
Set B Size (bp) Target gene 
Internal control 850 CesA3 
CoV OC43 578 ORF1b 
HRV A/B/C 394 5’UTR 
HRSV A 269 F 
Influenza virus A 206 M1 
HRSV B 155 F 
Set C Size (bp) Target gene 
Internal control 850 CesA3 
HBoV 1/2/3/4 579 NS1 
Influenza virus B  455 NA 
HMPV 351 F 
PIV 4 249 HN 
EV 194 5’UTR 
bp: base pairs  
 Statistical Analyses 3.7
 Sample Size Calculation: 3.7.1
Published literature has reported HRSV ARI prevalence of 11.9% in Burkina Faso 
(Ouédraogo et al., 2014) and 10.7% in South Africa (Pretorius et al., 2016). The 
expected prevalence of HRSV in DRC might be as high as 10%.  With a level of 
significance at 95% and level of precision at 5%, the sample size must be 138 
patients.  
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The following formula was used for sample size calculation (Leslie, 1965): 
𝑛 = 1.96!𝑥 𝑆𝐷!𝑑!  𝑆𝐷 =  𝑝 1− 𝑝  
n: simple size 
d: level of significance  
p: expected prevalence  
 Summary Statistics 3.7.2
When analysed with the Shapiro test for normality (α level: 0.05), numerical data of 
this study displayed a non-parametric distribution and therefore, the median was 
used for the central tendency measure and the interquartile range (IQR) as the 
measure of dispersion. Categorical data, on the other hand, were summarized as 
proportions. 
 Analytical Analysis  3.7.3
Proportions and medians of the baseline characteristics variables were compared 
between the two groups of ARI (URTI versus LRTI) using the Chi-square test and the 
Mann-Whitney U test (two samples Wilcoxon test) respectively.  The Fisher test was 
used to compare proportions when the criteria for the Chi-square test were not met. 
Simple logistic regression was used to compute the OR ratio with 95% CI. The 
difference between two groups was statistically significant when the p-value was less 
than 0.05.  
To analyse independent association between baseline characteristics and LRTI, a 
multiple logistic regression model was built. This model included variables with a cut-
off of p-value < 0.1 in bivariate analyses. The null deviance and residual deviance 
were used to evaluate the overall performance of the model. The results of the model 
were reported as odds ratios and corresponding 95% CI.  
R software was used for statistical analyses.   
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CHAPTER 4: RESULTS 
 Baseline Characteristics of the Study Population: 4.1
A total of 146 children under the age of 5 years that were visiting the Paediatrics 
Department of the PGHB for ARI were recruited between August and December 
2016. The male to female ratio was 1 : 0.97. The median age of the study group was 
14.5 months (IQR 7-28), while the median gestational age was 38 weeks (range: 29-
41) and the median birthweight was 3 300g (range: 1 400-5 200g). The median 
number of siblings was 3 (IQR: 2-5) and 41 (28.1%) reported a family history of atopy. 
Other demographic factors included exposure to cigarette and cooking smoke in 19 
(13.0%) and 61 (41.8%) respectively and exposure to alcohol during pregnancy in 32 
(21.9%) of children. 
Table 4.1 summarizes the socio-demographic and relevant clinical information 
collected from the study group. 
Antibiotic treatment was initiated by the paediatrician in 60 children among which a 
viral infection was confirmed in 36 (60%) cases. The median symptom duration 
before the visit was 96 hours (range: 16-192). 
 HRSV Prevalence, non-HRSV ARI and Co-Infection 4.2
Of 146 samples analysed, 84 (57.5%) displayed a positive result for at least one of 
the 15 viruses. The prevalence of HRSV ARI was 21.2% (95% CI: 14.9-28.8). HRSV 
was detected in LRTI and URTI in 40.5% (95% CI: 24.8-57.9) and 14.7% (95% CI: 
8.6-22.7) of cases respectively. 
A total of 95 viruses were detected in 84 participants (Figure 4.1). HRSVA (30, 
20.5%) was the virus the most often detected, followed by HRV (24, 16.4%), PIV3 
(20, 16.7%) and ADV (7, 4.8%). Co-infection with two viruses occurred in 11 (7.5%) 
cases, with HRV being detected most often in the co-infected cases (Table 4.2). 
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Table 4.1 Sociodemographic and clinical information collected from the study group 
 Frequency Percentage 
Urban settings 129 88.4 
Household income level   
Low 47 32.2 
Middle 54 37.0 
High 45 30.8 
Maternal level of education   
Illiterate 22 15.1 
Primary school 30 13.7 
Secondary school 34 23.3 
University 70 48.0 
Malnutrition 40 27.4 
Admission to neonatology healthcare at birth 29 19.9 
Received oxygen 10/29 34.5 
Immunization up to date 120 82.2 
Exclusive breast feeding  71 48.6 
Antibiotic use prior to medical examination  47 32.2 
Antibiotic treatment initiated at medical examination 60 41.1 
Hospitalization 30 20.6 
Received oxygen 17/30 56.7 
Nasogastric intubation 12/30 40.0 
Diagnosis: LRTI 37 25.3 
Pneumonia 21/37 56.8 
Bronchiolitis 16/37 43.2 
Diagnosis: URTI 109 74.66 
Pharyngitis 38/109 34.9 
Otitis media 2/109 1.8 
Laryngitis 2/109 1.8 
Rhinitis 67/109 61.5 
URTI: Upper respiratory tract infection. LRTI: Lower respiratory tract infection. 
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Figure 4.1 Viruses detected by RT-PCR. Abbreviation of viruses 
detected and frequency.  
 
Table 4.2 Frequency of viruses detected in co-infected cases  
 Frequency 
ADV and HRV 1 
CoV OC43 and HRV 1 
PIV2 and ADV 1 
PIV2 and HRV 1 
PIV3 and HRV 3 
HRSVA and CoV OC43 1 
HRSVA and PIV3 2 
HRSVB and PIV3 1 
 
RSVA,	30	
HRV,	24	
PIV3,	20	
ADV,	7	
PIV2,	3	CoVOC,	3	
BoV,	2	CoV22,	2	 EV,	2	
FluA,	1	 RSVB,	1	
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 Risk Factors for ARI to be Diagnosed as LRTI 4.3
Table 4.3 summarizes bivariate analyses of the effect of different factors 
(demographics, clinical factors and HRSV status) on the risk of ARI being diagnosed 
as LRTI. Children with malnutrition had 2.67 times higher odds of ARI to be 
diagnosed as LRTI when compared to children without malnutrition (OR = 2.67, 95% 
CI: 1.1-6.3, p-value = 0.01). HRSV infection was associated with a 3.91-fold increase 
in the odds of LRTI (95% CI: 1.55-9.97, p-value < 0.001). Table 4.4 summarizes the 
effects of all the viruses that were detected in this study in relation to the odds of 
LRTI.  
The OR for LRTI in children from low versus high-income households was 3.13 (95% 
CI: 1.17-8.36, p-value = 0.010). This OR in children with illiterate mothers compared 
to children with mothers who attended university was 3.34 (95% CI: 1.14-9.79, p-
value = 0.020). Older children (by one month) had 5% lower odds of LRTI than 
younger children (OR = 0.95, 95% CI: 0.92-0.98, p-value = 0.006). 
A multiple logistic regression was performed to ascertain the effect of age, HRSV 
infection, immunization, malnutrition, history of atopy, maternal education, household 
income and settings on the likelihood of ARI to be diagnosed as LRTI (Table 4.5). Of 
the eight factors, only two were statistically significant: age and HRSV infection. 
Children with HRSV infection had 6.45 times higher odds to exhibit LRTI when 
compared to children without HRSV infection (adjusted OR (aOR) = 6.64, 95% CI: 
2.28-19.47, p-value < 0.001). Older children were less likely to have LRTI when 
compared to younger children (aOR = 0.94, 95% CI: 0.90-0.97, p-value = 0.004). 
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Table 4.3 Demographics and clinical findings of the population study grouped by the 
type of acute respiratory infection 
 URTI 
(N=109) 
LRTI 
(N=37) 
P-value OR 95% CI 
Gender (male)	 56(51.3) 16(43.2) 0.39 0.72 0.31-1.69 
Settings (rural)	 8(7.3) 9(24.3) 0.01 4 1.24-13.18 
Income	      
Low	 28(25.6) 19(51.3) 0.01 3.13 1.17-8.36 
Middle	 44(40.3) 10(27) 0.92 1.05 0.36-2.99 
High (ref.)	 37(33.9) 8(21.6)    
Maternal education	      
Illiterate	 13(11.9) 9(24.3) 0.02 3.34 1.14-9.79 
Primary	 14(12.8) 6(16.2) 0.21 2.07 0.64-6.67 
Secondary	 24(22) 10(27) 0.15 2.01 0.75-5.38 
University (ref.)	 58(53.2) 12(32.4)    
Cigarette smoke exposure	 14(12.8) 5(13.5) 0.91 1.05 0.27-3.43 
Cooking smoke exposure	 46(42.2) 15(40.5) 0.85 0.93 0.40-2.12 
Alcohol exposure	 25(22.9) 7(18.9) 0.61 0.78 0.25-2.12 
History of atopy	 35(32.1) 6(16.2) 0.06 0.41 0.12-1.12  
Neonatology stay	 21(19.2) 8(21.6) 0.75 1.15 0.39-3.08 
Oxygen therapy at birth	 7(6.4) 3(8.1) 0.71 1.28 0.20-6.01  
Malnutrition	 24(22) 16(43.2) 0.01 2.67 1.12-6.30  
Immunization status	 93(85.3) 27(72.9) 0.08 0.46 0.17-1.29  
Exclusive breast feeding	 58(53.2) 18(48.6) 0.99 1 0.44-2.25  
HRSV	 16(14.6) 15(40.5) <0.001 3.91 1.55-9.97  
Age *	 16 10 0.006 0.95 0.92-0.98 
Number of siblings *	 3 3 0.74 0.99 0.82-1.18 
Birthweight (gram)*	 3 300 3 300 0.85 1.00 0.99-1.00 
Gestational age (weeks)*	 34 34 0.64 1.09 0.00-1.72 
Symptoms duration (hours)*	 96 96 0.48 0.99 0.99-1.00 
Data are presented as n (%) or median*  
Ref. : parameter of reference 
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Table 4.4 Effects of respiratory viral infection confirmed by RT-PCR on the risk of LRTI 
among children under the age of 5 years at the Provincial General Hospital of Bukavu 
 RT-PCR URTI 
(n=109) 
LRTI 
(n=37) 
odds ratio (95% CI) P-value 
HRSVA Positive 15 15 4.22 (1.65-10.89) <0.001 
HRSVB Positive 1 0   
HRV Positive 17 7 1.92 (0.40-3.59) 0.63 
PIV2 Positive 3 0   
PIV3 Positive 15 5 0.97 (0.25-3.13) 0.96 
ADV Positive 5 2 1.18 (0.10-7.65) 1.00 
BoV Positive 1 1 2.97 (0.03-237.15) 0.44 
CoV229E Positive 2 0   
CoV OC43 Positive 2 1 1.48 (0.02-29.25) 1.00 
EV Positive 2 0   
Influenza 
virus A 
Positive 0 1   
URTI: Upper respiratory tract infection, LRTI: Lower respiratory tract infection, RT-PCR: 
Reverse Transcriptase Polymerase Chain Reaction 
Table 4.5 Logistic regression predicting likelihood of LRTI 
 B SE aOR CI p-value 
Age -0.06 0.20 0.94 0.90-0.97 0.004 
HRSV infection 1.86 0.54 6.45 2.28-19.47 <0.001 
History of atopy -0.65 0.57 0.51 0.15-1.53 0.25 
Immunization -0.37 0.66 0.62 0.18-2.60 0.57 
Income      
Low 1.53 1.07 4.64 0.58-41.97 0.15 
Middle 0.03 1.63 1.03 0.29-3.67 0.95 
Malnutrition 0.41 0.74 1.51 0.35-6.73 0.57 
Maternal education	     
Illiterate -0.42 1.17 0.65 0.05-6.10 0.71 
Primary -1.42 1.14 0.24 0.02-2.07 0.21 
Secondary -0.05 0.66 0.94 0.24-3.45 0.93 
Settings 1.39 0.79 4.02 0.89-20.75 0.07 
B: Slope, SE: Standard Error, aOR: Adjusted Odds Ratio 
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CHAPTER 5: DISCUSSION 
This cross-sectional study undertaken over 5 months at the PGHB is the first study to 
determine the overall burden of viral ARI in DRC. It aimed to analyse the 
epidemiological characteristics of ARI in children under the age of 5 years at the 
PGHB by setting two hypotheses. The first one stipulated that compared to other 
respiratory viruses the prevalence of HRSV is higher in ARI. The second 
hypothesized that HRSV, as well as some socio-demographic factors and medical 
features, is associated with the risk of ARI to be diagnosed as LRTI in children under 
the age of 5 years. These two hypotheses were confirmed: HRSV was the most 
prevalent virus in ARI and in bivariate analyses, HRSV infection, malnutrition, 
younger age, rural settings, low income and mother illiteracy were associated with 
the risk of ARI to be diagnosed as LRTI. However, in multivariate analyses, only 
HRSV infection and younger age predicted LRTI. 
 HRSV ARI Prevalence and Co-Infection 5.1
This study reports an overall HRSV prevalence (21.23%) similar to that reported in 
Kenya (17%) by Bigogo et al. (2013). However, this prevalence is slightly higher than 
what was reported in other countries of Africa: 14.1% in Ghana (Kwofie et al., 2012), 
11.9% in Burkina Faso (Ouédraogo et al., 2014), 10.7% in South Africa (Pretorius et 
al., 2016), 9.8% Mozambique (Loscertales et al., 2002) and 8.7% in Gambia (Weber 
et al., 2002). When considering only children with LRTI, the prevalence of HRSV is 
40.5%, a value much higher in respect to the prevalence reported in Tunisia (21.6%) 
by Fodha et al. (2004). Only one case of HRSV B infection was found, which is much 
lower than the 30 cases of HRSV A observed. This predominance of HRSV A over 
HRSV B has been previously observed in Burkina Faso as well as in Cyprus and in 
China even though there was a monthly distribution pattern involved (Ouédraogo et 
al., 2014; Panayiotou et al., 2014; Zheng et al., 2017). 
Some studies have suggested that the peak of HRSV prevalence appears to occur 
during the rainy season (Chan et al., 2002; Kwofie et al., 2012), other studies have 
reported that this peak occurs during the dry hot season (Forgie et al., 1991; Yoshida 
et al., 2013) and finally, others had failed to demonstrate any seasonality feature 
(Okiro et al., 2012; Haynes et al., 2013). Given that our findings are based on data 
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collected only during the rainy season of 2016, these results should be interpreted 
against the background of the season. It is therefore important to gain more insight 
into the HRSV seasonality in order to address prevention strategies of HRSV ARI in 
DRC.  
In this study, four cases of HRSV co-infection were detected, three of them with PIV3 
and one with CoV. Previously, PIV3 and CoV have been reported in cases of co-
infection with HRSV (Yoshida et al., 2013; Calvo et al., 2015). Yoshida et al. (2013) 
worked on children under 2 years of age hospitalized in Vietnam for LRTI and found 
that HRSV-PIV3 co-infection led to a high risk of pneumonia than single infection of 
any of these two viruses.  
No case of HRSV-influenza virus co-infection was observed during the study period 
and influenza virus was detected in just one case. In a study on the prevalence of co-
infection between HRSV and influenza virus in children conducted by Meskill et al. 
(2016) in Texas, the author observed 6 times less cases of HRSV-influenza virus co-
infection than expected during the seasons where these two viruses were co-
circulating and in the 2011-2012 season, the HRSV and influenza virus seasons did 
not overlap at all. Though, the theory of niche competition between these two viruses 
at the host level observed in several studies can be suggested. Using a mathematical 
model, Xicoténcatl Velasco-Hernández et al. (2015) has explained the alternating 
pattern of HRSV and influenza virus through the ecological hypothesis of competitive 
interaction between theses two viruses and niche availability. The author reported 
that HRSV is competitively superior to influenza virus and though, HRSV superinfects 
influenza virus allowing it to survive. In the case that influenza virus would superinfect 
HRSV, this would result in the extinction of the inferior competitor (influenza virus) 
leading a system of epidemics of HRSV only. These findings can lead us to 
hypothesize that there was probably an undocumented epidemic of influenza virus 
early during the year of our study period.  
HRV was the virus the most detected after HRSV in this study (16.4%); however, no 
case of HRSV-HRV co-infection has been observed. This virus is known to be 
involved in ARI in children (Onyango et al., 2012; Pretorius et al., 2012). Our findings 
contrast with previous results reported by Luchsinger et al. (2014) who found a 
sustainable degree of co-infection (22%) between these two viruses. However, the 
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work of Achten et al. (2017) on the interference of HRSV and HRV infection in 
infancy can explain our findings. The author has found evidence that support HRSV 
and HRV interference by demonstrating a negative association between these two 
viruses in ARI in infancy. He reported that children with HRSV infection had 83% 
lower odds of HRV infection than children without HRSV infection. Furthermore, he 
said that children who were on HRSV immunoprophylaxis had higher odds of HRV 
infection than those who were not on HRSV prophylaxis. Many other studies have 
demonstrated this negative association pattern between HRSV and HRV (Greer et al., 
2009; Wisdom et al., 2009; Martin et al., 2013; Karppinen et al., 2016). 
PIV3 and ADV were the viruses that were detected most often in this study after 
HRSV and HRV. PIV3 was the virus most often involved in co-infection with HRSV. 
PIV3 is known to be an important agent of ARI in children in both URTI and LRTI 
(Mizuta et al., 2012; Frost et al., 2014). Although PIV3 infections are naturally mild 
and self-limiting, they can frequently cause severe diseases in immunocompromised 
people resulting in high rates of morbidity and mortality (Harvala et al., 2012). ADV is 
involved not only in respiratory infection, but also in gastroenteritis and conjunctivitis 
outbreaks (Dashti et al., 2016; Zhang et al., 2016). However, these conditions were 
not investigated during this study and no comment can be made on the possible 
association with ADV found. 
Two cases of BoV and EV were found in this study. BoV, a single-stranded DNA 
virus, was first discovered in 2005 and shown to be a cause of respiratory infection 
and gastroenteritis (Jartti et al., 2012), even though its role in human disease has not 
been well established yet. EV on the other hand, is a well-known virus involved in a 
wide spectrum of illness in children. Depending on the species, it can cause ARI, 
viraemia, herpangina, gastroenteritis, encephalitis and Hand-Foot-Mouth disease 
(Tapparel et al., 2013).  
PIV 1 and 4, influenza virus B, and HMPV were not detected this study at all, but are 
recognized in the literature as usual pathogens of the respiratory tract in children.  
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 Risk Factors for LRTI 5.2
 Age 5.2.1
This study highlights the independent association between younger age and the risk 
of LRTI. This has been documented in previous studies and supports findings in the 
literature (Ujunwa & Ezeonu, 2014). The relatively immature immune system and 
poor compliance of immature bronchioles can explain why young children are more 
at risk for LRTI when compared to older children (Nathan et al., 2014). In a rat model, 
Martin et al. (1995) has revealed the evidence of postnatal impairment of TLR2 and 
TLR4 expression when lungs epithelium was exposed to exogenous antigens. In 
infants, the level of adaptive immunity is also reduced and it was reported that both 
CD4 and CD8 functions are deficient which can lead to reduced viral clearance 
(Tregoning & Schwarze, 2010). 
 HRSV Infection 5.2.2
A very important finding of this study was that HRSV was independently associated 
with the risk of ARI to be diagnosed as LRTI. This substantiates previous studies in 
the literature all around the world (Singleton et al., 2010; Al-Ayed et al., 2014; 
Ouédraogo et al., 2014). HRSV displays some specific characteristics that make it 
very prevalent and highly infectious. This includes high infectivity, tropism to the 
superficial respiratory epithelium (that reduces the effectiveness of the host immunity 
response), expression of type I IFN antagonists, proteins that inhibit apoptosis, 
capacity of reinfection throughout the life, expression of fractalkine and TLR 
antagonists, interference with normal macrophage and DC function (Collins & 
Graham, 2008).  
 Other Factors 5.2.3
Even though malnutrition, rural settings, low income and mother illiteracy were 
associated with the risk of LRTI in bivariate analyses, this study failed to find an 
independent association with any of these factors. This is in contrast to a study done 
in Kenya, Okiro et al. (2008) that has demonstrated an independent association 
between malnutrition, the presence of 2 or more smokers in the household, illiteracy 
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of primary caretakers, a number of family children of eleven or more and the risk of 
LRTI. Moreover, our study also failed to demonstrate any kind of association 
between LRTI and gender, cigarette and smoke exposure, alcohol exposure during 
pregnancy, family history of atopy, exclusive breastfeeding, immunization status, high 
numbers of siblings, prematurity or low birthweight. Jackson et al. (2013) published a 
meta-analysis on the risk factors for severe LRTI in children. The author identified 36 
studies that investigated 19 risk factors among which 7 were significantly associated 
with severe LRTI: low birth weight, lack of exclusive breast feeding, crowding (more 
than 7 persons per household), exposure to indoor air pollution, incomplete 
immunization, undernutrition (weight for age < 2 standard deviation) and HIV 
infection.  
Weight for age was used in this study as the nutritional index because in the 
database the height measurement was missing in some participants. It was therefore 
not possible to assess stunting (low height for age) and wasting (low weight for 
height).  
 Strengths and Limitations: 5.3
 Strengths: 5.3.1
This study was performed in a provincial referral hospital and therefore included 
patients from different areas. The findings of this study can therefore be 
generalizable to all the Province of South Kivu. Moreover, the sample size used was 
representative of the study population. 
In contrast to many studies in the literature which usually investigate only a few viral 
agents involved in ARI in children, this study investigated 15 different viruses at the 
same time. 
This is the first study on viral aetiology of ARI in children in DRC. Standardized 
approaches were used and therefore, this study can be replicated in other places of 
the country. 
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 Limitations: 5.3.2
This study did not assess the role of bacteria in the aetiologies of ARI. There are 
some gaps that remain on the epidemiology of ARI.  
It was not possible to assess seasonality of viruses involved in ARI, due to limited 
time available for this study. This should be followed up with bigger studies over 
longer periods of time to elucidate the effect of seasons on different individual viruses 
and co-infections.  
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS: 
 Conclusion 6.1
As expected, the prevalence of HRSV is high among children visiting the PGHB for 
ARI. HRSV infection and lower age are independently associated with the risk of ARI 
to be diagnosed as LRTI. 
 Recommendations 6.2
After thorough analysis of the findings, the following recommendations are offered: 
Ø Medical practitioners should use antibiotics cautiously in children with ARI.  
Ø IPC measures should be reinforced:  
• Caregivers should wash their hands before and after touching a patient.  
• Caregivers should use gloves and gowns.  
•  Rapid methods for early detection of HRSV infection should be implemented. 
• Infected patients and caregivers should be cohorted. 
• Visitors should be advised about a possible risk of transmission. 
Ø A national active surveillance program for HRSV infection should be set up and 
performed during high risk seasons to identify disease patterns. 
Ø Further studies on ARI in children with a lengthy period of study to should be 
carried out so as to determine the seasonality of HRSV and other viruses 
involved in ARI. 
Ø Studies on the role of bacteria in ARI should be conducted. 
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CHAPTER 8: APPENDICES 
APPENDIX 1: Stellenbosch University RSV study ethical approval  
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APPENDIX 2: Catholic University of Bukavu RSV study ethical approval (French 
version) 
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APPENDIX 3: Catholic University of Bukavu RSV study ethical approval (English 
version) 
Catholic University of Bukavu 
Institutional Ethics Committee  
BP 285 BUKAVU (Democratic Republic of Congo) 
Phone number: (00243) 813181718 and 0992838793 
Site: www.ucbukavu.cd 
Ref number: UCB/CIE/NC/013/2016 
Object: Our point 
Dr Landry Kabego 
Student number: 20321848 
Virology Laboratory, Stellenbosch University 
Tygerberg Campus 
The Institutional Ethics Committee of the Catholic University of Bukavu has the pleasure to 
let you know that your research project was approved.  
Your study protocol named: Prevalence and risk factors of respiratory infections by 
respiratory syncytial virus in children at Provincial General Hospital of Bukavu (PGHB), 
Bukavu City, Democratic Republic of Congo (DRC) was approved and the reference 
number for the protocol is UCB/CIE/NC/013/2016. 
We remind you that the committee makes its decisions on the following features: 
1. The pertinence of the protocol 
2. Respect of human beings (informed consent, harmfulness, risk-benefit ratio…) 
3. The methodology 
Many thanks for your collaboration. 
Kind regards 
Date and place of Issue: The 4th of June 2016, Bukavu 
Stamp: Catholic University of Bukavu. 
Signature: Professor Bagendabanga Macece, secretary of the Institutional Ethics committee 
of the Catholic University of Bukavu.  
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APPENDIX 4: RSV study consent form 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: 
Prevalence and risk factors of respiratory infection by Respiratory Syncytial Virus in children 
at Provincial General Hospital of Bukavu 
REFERENCE NUMBER: S16/03/051 
PRINCIPAL INVESTIGATOR: Dr Landry Kabego C. 
ADDRESS:  Division of Medical Virology, Faculty of Medicine & Health Sciences, Tygerberg 
Campus 
CONTACT NUMBER: +243992048827, +27626386130, 021 938 9354 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.  Also, your participation is entirely 
voluntary and you are free to decline to participate.  If you say no, this will not affect you 
negatively in any way whatsoever.  You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
This study has been approved by the Ethics Committee of the Catholic University of 
Bukavu and the Health Research Ethics Committee at Stellenbosch University and will 
be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
Ø This study will be conducted at the Provincial General Hospital of Bukavu, 
Democratic Republic of Congo. Between 1st June 2016 and 31st May, all children 
under 5 years of age with signs of respiratory infections will be approached to take 
place to this study. We expect to enrol approximately 152 children in this study.  
Ø Respiratory infections are very frequent in childhood, and the number of deaths is 
very high. Viruses are a major cause of respiratory infections in children. Here in 
Bukavu, little baseline information is available on acute respiratory infection. The aim 
of this study is to identify the role of viruses in acute respiratory infection in children 
and therefor to manage them correctly. Moreover, this study will allow us to set a 
system of infection control and any outbreak that may arrived will be managed to 
avoid infection propagation.  
Ø When your children will be approached, a medical doctor will do a complete 
examination. Routine samples will be taken and, if you accept that your child 
participates, a Perinasal Flocked swab will be done on him/her. The process is very 
simple. The physician will introduce gently a swab in your child’s nose and will rotate 
it five times and pull it out. It will take no longer than 10 seconds. It can be 
uncomfortable procedure and can cause slight pain however.  
Ø No medication will be used.  
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Why have you been invited to participate? 
Ø Your child has been invited to participate because he or she has a respiratory 
infection which may be caused by viruses.  
What will your responsibilities be? 
Ø You will be expected to answer questions about your child’s history  
Will you benefit from taking part in this research? 
Ø You will not benefit directly from this study. However, the results obtained may 
considerably improve children’s health in this region.  
Are there in risks involved in your taking part in this research? 
If perinasal flocked swab is performed improperly it can cause minor trauma. However, our 
medical staffs are well trained and therefore we don’t expect any injury to occur. But if any 
form of injury occurs, the medical staff will look after your child.  
If you do not agree to take part, what alternatives do you have? 
Your participation is completely voluntary. If you do not want to participate, it will not affect 
your child’s care in any way. You are also free to withdraw from the project at any point, even 
if you did agree to take part. 
Who will have access to your medical records? 
The information collected will be confidential. Your name will not appear in the data base and 
will be replaced by a code, so you will remain anonymous. Only the research staff will have 
access to the information.  
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
If any injury occurs, your child will be looked after by the medical staff.  
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part to this study.  You won’t have to pay for the tests being done 
for this study. 
Is there any thing else that you should know or do? 
Ø You can contact Dr Landry Kabego at tel +24399204882 / +27626386130 if you have 
any further queries or encounter any problems. 
Ø You can contact the Ethics Committee of the Catholic University of Bukavu at +243 
813181718 and the Health Research Ethics Committee at +27 21-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by your 
study doctor. 
Ø You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled (insert title of study). 
I declare that: 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
Signed at (place) ......................…........ on (date) …………....……….. 201... 
 
 ....................................................................   .................................................................. 
Signature of participant Signature of witness 
 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
Signed at (place) ......................…........ on (date) …………....……….. 201... 
 
 ....................................................................   .................................................................. 
Signature of investigator Signature of witness 
Stellenbosch University  https://scholar.sun.ac.za
 
66 
Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
• I assisted the investigator (name) ………..…………………………………. to explain 
the information in this document to (name of 
participant) ……………..……………………….. using the language medium of 
French/Swahili. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........……… on (date) ……………………….. 
 ....................................................................   .................................................................. 
Signature of interpreter Signature of witness 
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APPENDIX 5: RSV study questionnaire 
QUESTIONNAIRE 
Prevalence and risk factors of respiratory infection by Respiratory Syncytial Virus in 
children at Provincial General Hospital of Bukavu 
ID : 
Age:                             months     
Gender:  Male         Female          
Weight:        gr     Height:          cm     
Malnutrition: Acute Chronic 
Birthweight:               gr         Gestational age:        weeks 
Neonatology stay:    Yes No 
Oxygen treatment in neonat.: Yes No   
Socio-economic status: Poor Middle Rich     
Mother education: Illiterate             Primary           Secondary            University 
Antibiotics before visit: Yes              No 
Symptoms duration (hours): 
Immunization up to date : Yes             No 
Breastfeeding (months):  
Siblings: 
Smoke exposure: Cigarette                Cooking smoke   
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Alcohol exposure during pregnancy: Yes        No   
Congenital heart diseases:  
Chronic lung diseases: 
Familial history of atopy: Asthma              Urticaria           Others  
URTI: Rhinitis            Otitis               Pharyngitis              Laryngitis                                                               
LRTI: Pneumonia Bronchiolitis   
Antibiotic treatment: Yes           No  
Oxygen treatment: Yes              No 
Nasograstric intubation: Yes                 No  
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APPENDIX 6: South Africa import permit 
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APPENDIX 7: DRC export permit 
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